1998
DOI: 10.1590/s0104-42301998000400007
|View full text |Cite
|
Sign up to set email alerts
|

Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus

Abstract: SUMMARY -Were selected 18 SLE patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous patients (ACR criteria) with active cutaneous lesions not responsive to chloroquine, photolesions not responsive to chloroquine, photolesions not responsive to chloroquine, photolesions not responsive to chloroquine, photolesions not responsive to chloroquine, photoprotectors and low doses prednisone… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
12
0
4

Year Published

1999
1999
2012
2012

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 38 publications
(19 citation statements)
references
References 30 publications
3
12
0
4
Order By: Relevance
“…In line with previous studies, we also did not observe differences in clinical responses between discoid and subacute lupus erythematosus lesions. 3,8 Similar to other series, a high rate of relapse (85%) in patients who stopped thalidomide was observed. 2,3 The presence of paresthesia without clinical or electrophysiologic findings was also found in our series, in similarity with previous reports.…”
Section: Discussionsupporting
confidence: 83%
“…In line with previous studies, we also did not observe differences in clinical responses between discoid and subacute lupus erythematosus lesions. 3,8 Similar to other series, a high rate of relapse (85%) in patients who stopped thalidomide was observed. 2,3 The presence of paresthesia without clinical or electrophysiologic findings was also found in our series, in similarity with previous reports.…”
Section: Discussionsupporting
confidence: 83%
“…Of further interest in this respect is the observation that glomerulonephritis is significantly milder in TNF␣Ϫ/Ϫ mice (11). In further support of such a role, glucocorticoids and thalidomide, 2 agents that also inhibit TNF␣ (13,14), are successfully used for certain disease manifestations of SLE (15,16). In further support of such a role, glucocorticoids and thalidomide, 2 agents that also inhibit TNF␣ (13,14), are successfully used for certain disease manifestations of SLE (15,16).…”
Section: Role Of Tumor Necrosis Factor ␣ and Potential Benefit Of Tummentioning
confidence: 98%
“…Thalidomide, a glutamic acid derivative, has been used successfully in a variety of chronic refractory inflammatory dermatological conditions with an underlying autoimmune or infectious pathogenesis 8 . It was first used in the treatment of systemic lupus erythematosus (SLE) in 1975, and, since then, there has been renewed interest and increased use following its reported effectiveness, reaching 80–90% according to different studies 9–17 . Despite these studies proving its general efficacy, it is still not clear if the clinical response might differ among cutaneous subtypes, and, to date, no attempts have been made to find possible prognostic factors of clinical response.…”
mentioning
confidence: 99%